Study of DPTX3186 for advanced solid tumors with Wnt pathway activation
Part of Cancer clinical trials.
This trial tests an experimental oral drug (DPTX3186) for people with advanced solid tumors that are linked to the Wnt pathway. It may be an option if standard treatments are no longer available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your type of cancer is one that may be linked to the Wnt pathway (like colorectal, gastric, lung, or triple-negative breast cancer) and you have no other approved treatment options.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are able to be up and about (fully active or with a little help) – that's an ECOG score of 0 or 1.
- You do not have a condition that would prevent you from swallowing or absorbing oral medicine (like a colostomy or ileostomy).
- You are 18 or older and expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called WTX212A for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to find the best dose and see if the drug is safe and effective.
This early-stage trial tests a new drug called DXP-106 in patients with advanced cancers (like lung, pancreatic, or breast cancer) that have stopped responding to standard treatments. The study aims to find the right dose and see if this drug can help slow or shrink these tumors.
This early-phase trial tests an experimental drug called STP938 (Dencatistat) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works against different cancer types.
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
This trial tests a new drug called PTX-912 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It is a first-in-human study, meaning this is the first time PTX-912 is being given to people, to see how safe it is and how well it works.
This trial tests a new drug called PTT-4256 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it helps shrink or control the cancer.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.